Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Heart of the Family: A Cardiovascular Disease and Type 2 Diabetes Risk Reduction Intervention in High-Risk Rural Families
Rural populations in the U.S. are disproportionately burdened by cardiovascular disease and type 2 diabetes. Lifestyle modification interventions are needed that support long-term engagement in risk-reducing health behaviors. This trial will study the effects of a family-focused, lifestyle intervention that is culturally tailored for use with rural Hispanic and non-Hispanic adults. If successful, this community-based intervention has significant potential for broad dissemination to reduce cardiovascular disease and type 2 diabetes health disparities in rural U.S. communities.
| Status | Recruiting |
| Enrollment | 540 |
| Est. completion date | February 11, 2026 |
| Est. primary completion date | January 1, 2026 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: Primary participants are rural-dwelling Hispanic and non-Hispanic adults who are at-risk for type 2 diabetes or cardiovascular disease and have a family member who is willing to participate if the primary participant is randomly selected to participate with a family member. Inclusion criteria for the primary participant: - Is Hispanic or non-Hispanic adult - Is 18 years of age and older - Is a primary Spanish or English speaker - Has internet access - Has two or more risk factors for type 2 diabetes or cardiovascular disease including: 1. clinical diagnosis of hypertension; 2. clinical diagnosis of hyperlipidemia; 3. clinical diagnosis of prediabetes; 4. overweight or obese (body mass index = 25 kg/m2); 5. is a current cigarette smoker; 6. male 45 years of age or older or female 55 years of age or older; 7. family history in first degree relative of type 2 diabetes or cardiovascular disease; or 8. is a female with a history of gestational diabetes mellitus or polycystic ovary syndrome. - Lives in rural Kentucky - Is willing to participate in the study for the next 12 months Inclusion criteria for the co-participating family member if primary participant is randomly selected to participate with a family member - Is 18 years of age and older - Is a primary Spanish or English speaker - Lives in the same household or in close proximity (no further than 25 miles distance) to the primary participant - Has internet access - Is willing to participate in the study for the next 12 months Exclusion Criteria: Exclusion criteria for family dyads: Primary participant and family member participant will be excluded if they: - Have cognitive impairment that preclude them from understanding the consent process, answering questionnaires, or participating in the intervention; - Have a major psychiatric (e.g., schizophrenia) condition; - Are pregnant or nursing or plan on becoming pregnant within the next year since dietary needs will be different. Exclusion criteria that apply only to the primary participant: - Have known coronary artery or cerebrovascular disease; - Have a diagnosis of type 1 or type 2 diabetes; - Have medical contraindications to participate in a lifestyle intervention that includes unsupervised physical activity and weight loss |
| Country | Name | City | State |
|---|---|---|---|
| United States | 2201 Regency Rd. | Lexington | Kentucky |
| Lead Sponsor | Collaborator |
|---|---|
| Gia Mudd | National Institute of Nursing Research (NINR) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in body mass index (BMI) | BMI based on measurements of weight and height and calculated as kg/m2. | 1 year (baseline, 3 months and 12 months) | |
| Primary | Change in blood pressure | Blood pressure assessed using calibrated sphygmomanometry. | 1 year (baseline, 3 months and 12 months) | |
| Primary | Change in lipid profile | Lipid profile includes LDL-cholesterol, HDL-cholesterol and triglycerides measured using point-of-care testing obtained by fingerstick. | 1 year (at baseline, 3 months and 12 months) | |
| Primary | Change in hemoglobin A1c (HbA1c) | HbA1c will be measured using point-of-care testing obtained by fingerstick. | 1 year (at baseline, 3 months and 12 months) | |
| Primary | Change in physical activity level | Physical activity will be measured using the International Physical Activity Questionnaire (IPAQ) to assess the number of days in the last 7 days that the participant engaged in vigorous or moderate physical activity and confirmed by comparing responses to activity levels as determine through actigraphy. | 1 year (at baseline, 3 months and 12 months) | |
| Primary | Change in dietary intake patterns | Dietary intake patterns will be assessed using the Vioscreen food frequency questionnaire. | 1 year (at baseline, 3 months and 12 months) | |
| Primary | Change in tobacco use | Tobacco use will be confirmed by collection of a saliva sample to determine cotinine levels. | 1 year (at baseline, 3 months and 12 months) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |